Brad Kahl, MD

Medical Oncologist

Brad Kahl

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Gary C. Werths Building at Siteman Cancer Center

Gary C. Werths Building at Siteman Cancer Center

On WashU Medicine Campus
4500 Forest Park Avenue, Saint Louis, MO 63108

Expertise & Training

Video thumbnail for Brad Kahl, MD Medical Oncologist

Watch video on YouTube

Brad Kahl, MD Medical Oncologist

5 mins

Brad Kahl, MD, a Medical Oncologist at Siteman Cancer Center, shares how he shares the big picture with every cancer patient and why that is so important.

Clinical Expertise

  • Hematologic malignancies, lymphoma, chronic lymphocytic leukemia

Primary Academic Title

Professor of Medicine, Division of Oncology Director, Lymphoma Program, WashU Medicine

Board Certification

  • 1997: American Board of Internal Medicine
  • 2001: American Board of Internal Medicine - Hematology
  • 2011: American Board of Internal Medicine - Hematology

Training

  • 1994 - 1998: Resident, Internal Medicine, University of Wisconsin, Madison, WI
  • 1998 - 2000: Fellow, Hematology, University of Wisconsin, Madison, WI

Education

  • 1994: MD, Tufts University School of Medicine, Boston, MA

Research & Selected Publications

Research Interest

My interests involve clinical and translational efforts to improve outcomes for lymphoma patients. I am particularly interested in novel agents and testing of those agents in clinical trials. I have led several clinical trials in the Eastern Cooperative Oncology Group and currently serve as Chair of the ECOG Lymphoma Committee.

Research Publications

A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma
Authors:

Diefenbach CS, Jegede O, Wang V, one or more additional authors omitted Kahl BS

Journal & Year:

Blood | 2026

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy
Authors:

Wang Y, Larson MC, Hwang SR, one or more additional authors omitted Kahl BS, one or more additional authors omitted Martin P

Journal & Year:

Blood Cancer J | 2026

Gene expression profiling reveals 2 overarching types of ALCL with distinct targetable biology: an LLMPP study
Authors:

Feldman AL, Dasari S, Rimsza LM, one or more additional authors omitted Kahl BS, one or more additional authors omitted Aljudi AA

Journal & Year:

Blood | 2026

NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026
Authors:

Wierda WG, Brown J, Abramson JS, one or more additional authors omitted Kahl B, one or more additional authors omitted Sundar H

Journal & Year:

J Natl Compr Canc Netw | 2026

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma
Authors:

Maurer MJ, Prochazka VK, El-Galaly TC, one or more additional authors omitted Kahl BS, one or more additional authors omitted Cerhan JR

Journal & Year:

J Clin Oncol | 2026

Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma
Authors:

Alderuccio JP, Baggio D, Han S, one or more additional authors omitted Kahl BS, one or more additional authors omitted Cwynarski K

Journal & Year:

Blood | 2026

Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed Therapies
Authors:

Atallah-Yunes SA, Nze CC, King RL, one or more additional authors omitted Kahl BS, one or more additional authors omitted Wang Y

Journal & Year:

Am J Hematol | 2025

Converging approaches in the frontline treatment of mantle cell lymphoma
Authors:

Patel DA, Kahl BS

Journal & Year:

Clin Adv Hematol Oncol | 2025